Abstract

Dilemma in post-IBD patients with IBS-D symptoms; A 2020 overview

Expert Rev Gastroenterol Hepatol. 2020 Sep 29. doi: 10.1080/17474124.2021.1829469.Online ahead of print.

Mukaddes Tozlu 1, Brooks Cash 1, Atilla Ertan 1

 
     

Author information

  • 1University of Texas McGovern Medical School , Gastroenterology, Hepatology and Nutrition Section; Ertan Digestive Disease Center, Houston, Texas.

Abstract

Introduction: Inflammatory bowel disease (IBD) patients in apparent clinical remission who present with irritable bowel syndrome (IBS)-like symptoms pose a diagnostic and therapeutic dilemma that is called post-IBD IBS. When associated with a diarrheal IBS presentation, this clinical syndrome is known as post-IBS IBS-D.

Areas covered: We review and describe the literature regarding the clinical overlap of IBD and IBS. We discuss prevalent theories regarding the pathophysiology of post-IBD IBS-D and whether this presentation represents coincident inherent IBS-D, IBS-D triggered by IBD, or an even more subtle level of IBD activity that is unrecognized by available laboratory modalities. We also discuss observations that post IBD IBS-D patients harbor significantly increased colon mucosal eosinophils and appear to respond to a GI-hypoallergenic diet and budesonide therapy.

Expert opinion: The symptoms overlap between IBD and IBS complicates diagnosis and subsequent management of patients with post-IBD IBS-D. In addition to current theories regarding the pathophysiology of this condition such as alterations in mucosal inflammation, the microbiota, mucosal permeability, and gut-brain interactions. This new avenue of eosinophilic colopathy and therapy directed towards food-derived immune response in patients with post-IBD IBS-D deserves additional investigation.

© Copyright 2013-2020 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.